Shenqi Fuzheng injection combined with GP chemotherapy in the treatment of advanced non-small cell lung cancer: a meta-analysis

摘要

Abstract Objective: To evaluate the clinical efficacy of Shenqi Fuzheng injection combined with gemcitabine plus cisplatin (GP) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: we performed a systematic search in the electronic databases such as Cochrane Library, Pubmed, Embase, Chinese Journal Full-text Database, Chinese Biomedical Literature Database, Chinese Science and Technology Periodical Full-text Database and Wanfang Database up to 30 January 2017. Randomized controlled trials (RCT) of Shenqi Fuzheng Injection combined with GP chemotherapy in the treatment of advanced NSCLC were searched, and all the RCTs were conducted on methodological quality assessment. Data extraction and data analysis were according to standards of Cochrane systematic review. Results: Eight trials were included including a total of 701 patients. Meta-analysis results: Shenqi Fuzheng injection combined with GP chemotherapy could significantly improve the functional status of patients with NSCLC (OR = 3.44, 95% CI [2.26, 5.25], P < 0.0001) and clinical treatment efficacy (OR = (OR = 0.31, 95%CI [0.20, 0.47], P < 0.0001. The rate of leukopenia (OR = .31, 95%CI [0.20,0.47], P < 0.0001), thrombocytopenia (OR = 0.58, 95%CI [0.37, 0.91], P = 0.020), hemoglobin decline ((OR = 0.31, 95%CI [0.16, 0.59], P = 0.0004) and incidence of gastrointestinal reactions (OR = 0.58,P < 0.05) could be reduced. Conclusion: Shenqi Fuzheng injection combined with GP chemotherapy in the treatment of advanced NSCLC obtained significantly clinical efficacy. The quality of the literature incorporated is low, the conclusion requires high-quality research to further prove.